Kirner Alexandra, Mayer-Mokler Andrea, Reinhardt Carsten
a Immatics Biotechnologies GmbH ; Tübingen , Germany.
Hum Vaccin Immunother. 2014;10(11):3179-89. doi: 10.4161/21645515.2014.983857.
Despite a major improvement in the treatment of advanced kidney cancer by the recent introduction of targeted agents such as multi-kinase inhibitors, long-term benefits are still limited and a significant unmet medical need remains for this disease. Cancer immunotherapy has shown its potential by the induction of long-lasting responses in a small subset of patients, however, the unspecific immune interventions with (high dose) cytokines used so far are associated with significant side effects. Specific cancer immunotherapy may circumvent these problems by attacking tumor cells while sparing normal tissue with the use of multi-peptide vaccination being one of the most promising strategies. We here summarize the clinical and translational data from phase I and II trials investigating IMA901. Significant associations of clinical benefit with detectable T cell responses against the IMA901 peptides and encouraging survival data in treated patients has prompted the start of a randomized, controlled phase III trial in 1st line advanced RCC with survival results expected toward the end of 2015. Potential combination strategies with the recently discovered so-called checkpoint inhibitors are also discussed.
尽管近期引入多激酶抑制剂等靶向药物后，晚期肾癌的治疗有了重大改善，但长期获益仍然有限，该疾病仍存在重大未满足的医疗需求。癌症免疫疗法已在一小部分患者中诱导出持久反应，显示出其潜力，然而，迄今为止使用的（高剂量）细胞因子进行的非特异性免疫干预会带来显著副作用。特异性癌症免疫疗法可以通过攻击肿瘤细胞同时保护正常组织来规避这些问题，使用多肽疫苗接种是最有前景的策略之一。我们在此总结了研究IMA901的I期和II期试验的临床及转化数据。临床获益与针对IMA901肽的可检测T细胞反应之间的显著关联以及治疗患者中令人鼓舞的生存数据，促使在一线晚期肾细胞癌中开展一项随机对照III期试验，预计2015年底得出生存结果。还讨论了与最近发现的所谓检查点抑制剂的潜在联合策略。
